alexa Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M ACAC AN

Abstract Share this page

Abstract The routine use of integrase inhibitors in sub-Saharan Africa where HIV-1 non-B viruses predominate is limited, but evaluating their effectiveness on HIV-1 subtypes and CRFs that circulate in this region is essential. We here analyzed 97 integrase sequences from HIV-1 non-B-infected individuals from African countries. Using currently available interpretation algorithms (ANRS, HIVdb, and Rega), we identified the presence of mutations at nine resistance-associated positions including L74M (3.1\%), T97A (9.3\%), K156N (2.1\%), E157Q (5.2\%), G163K (1.0\%), T206S (48.5\%), S230N (1.0\%), D232N (1.0\%), and R236K (1.0\%). All but one (E157Q) were considered as accessory resistant mutation by the algorithms. E157Q identified in 5\% of patients tested (5/97) was selected by the ANRS algorithm as a primary mutation, which alone can confer resistance to raltegravir. These results illustrated the need of further in vitro and clinical studies involving non-B viruses to better understand the real significance of observed mutations and harmonize interpretations. This article was published in AIDS Res Hum Retroviruses and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords